| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 15 |
| 1 | ETOPOSIDE | 15 |
| 2 | DEXAMETHASONE | 14 |
| 3 | DEXAMETHASONE 1.5 MG | 14 |
| 4 | APREPITANT | 13 |
| 5 | FOSAPREPITANT DIMEGLUMINE | 13 |
| 6 | ONDANSETRON | 10 |
| 7 | ONDANSETRON HYDROCHLORIDE | 10 |
| 8 | ONDANSETRON TABLETS | 10 |
| 9 | AZATHIOPRINE | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FOSAPREPITANT DIMEGLUMINE | 13 | 0.0010 |
| 1 | APREPITANT | 13 | 0.0007 |
| 2 | ETOPOSIDE | 15 | 0.0002 |
| 3 | CISPLATIN | 15 | 0.0002 |
| 4 | BLEOMYCIN SULFATE | 1 | 0.0001 |
| 5 | IFOSFAMIDE FOR INJECTION | 2 | 0.0001 |
| 6 | ONDANSETRON TABLETS | 10 | 0.0001 |
| 7 | ESTRADIOL TRANSDERMAL | 4 | 0.0001 |
| 8 | CEFAZOLIN SODIUM | 1 | 0.0001 |
| 9 | ONDANSETRON HYDROCHLORIDE | 10 | 0.0001 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 17 |
| 1 | Platinum-based Drug [EPC] | 15 |
| 2 | Topoisomerase Inhibitor [EPC] | 15 |
| 3 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 13 |
| 4 | Serotonin-3 Receptor Antagonist [EPC] | 10 |
| 5 | Aldosterone Antagonist [EPC] | 4 |
| 6 | Estrogen [EPC] | 4 |
| 7 | Purine Antimetabolite [EPC] | 4 |
| 8 | Alkylating Drug [EPC] | 2 |
| 9 | Atypical Antipsychotic [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 13 | 0.0007 |
| 1 | Topoisomerase Inhibitor [EPC] | 15 | 0.0002 |
| 2 | Serotonin-3 Receptor Antagonist [EPC] | 10 | 0.0001 |
| 3 | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] | 1 | 0.0001 |
| 4 | Platinum-based Drug [EPC] | 15 | 0.0001 |
| 5 | Purine Antimetabolite [EPC] | 4 | 0.0000 |
| 6 | Aldosterone Antagonist [EPC] | 4 | 0.0000 |
| 7 | Estrogen [EPC] | 4 | 0.0000 |
| 8 | Corticosteroid [EPC] | 17 | 0.0000 |
| 9 | Alkylating Drug [EPC] | 2 | 0.0000 |